H. Lundbeck A/S (LUN.CO) Release: Vortioxetine, a New Multimodal Agent in Development for the Treatment of Major Depression, Shows Effects on Cognitive Function in Several Preclinical Animal Models
5/22/2013 9:34:58 AM
More...
|
Positive Trial Results for Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO)'s Abilify Maintena in Schizophrenia
5/22/2013 6:56:52 AM
More...
|
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1
5/21/2013 10:55:14 AM
More...
|
H. Lundbeck A/S (LUN.CO) – Admittance to Trading and Official Listing of New Shares Due to Exercise of Warrants
5/21/2013 9:32:52 AM
More...
|
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO) Enter $825 Million Deal for Alzheimer's Drug
3/26/2013 7:03:04 AM
More...
|
Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S (LUN.CO) Wins Approval for Monthly Abilify Shot
3/1/2013 7:26:41 AM
More...
|
Lennox-Gastaut Syndrome Foundation and H. Lundbeck A/S (LUN.CO) Announce Scholarship
1/23/2013 9:51:51 AM
More...
|
Patient Groups Give H. Lundbeck A/S (LUN.CO) Top Marks
1/14/2013 8:43:56 AM
More...
|
H. Lundbeck A/S (LUN.CO) Appoints New Vice President of Global Pricing and Market Access
1/11/2013 9:35:15 AM
More...
|
Vernalis PLC (VNLPY.PK) and H. Lundbeck A/S (LUN.CO) Achieve Third Research Milestone
1/2/2013 10:11:45 AM
More...
|
|